2016-2017 Xpert Perspectives on Ulcerative Colitis in Europe
(English)

Viewing Options

Webcast

Topic Information

Goal Statement

The goal of the 2016-2017 Xpert Perspectives on Ulcerative Colitis in Europe On-Demand Series is to deliver focused updates highlighting the most clinically relevant advances in treatment decisions for patients with UC throughout Europe.

Target Audience

The target audiences for this initiative are gastroenterologists, specialist nurses and general practitioners. Siyemi and the GiHF believe this program will enhance the professional effectiveness of program participants of treating their patients with ulcerative colitis, benefiting patients under their care.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Develop strategies to select the optimal therapeutic goal and treatment choices for UC

Describe the effect that UC has on patient quality of life

Implement strategies for incorporating recently approved and emerging therapies for UC

Define "biosimilars" and discuss the scientific concept, "real world" data and benefits

Analyze recently approved and emerging therapies for UC

Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and GI Health Foundation. Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians.

Siyemi Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: June 6th, 2017
Expiration Date: June 6th, 2018

Disclosure statement

James Lindsay, MD:
Honorarium/ Advisory Board: Abbvie, Allergan, Atlantic Healthcare, Celltrion, Ferring, Janssen, Pfizer, MSD, Shire and Takeda
Research Grant: Takeda and Pfizer

Peter Irving, MD:
Advisory Board: AbbVie, Genentech, Hospira, Janssen, MSD, Pharmacosmos, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma and Warner Chilcott
Research Grant: Janssen, MSD and Takeda
Speaker: AbbVie, Warner Chilcott, Ferring, Falk Pharma, Takeda, Tillotts, MSD, Janssen and Shire

All staff at Siyemi Learning and GiHF have no relevant financial relationships to disclose.

This activity is supported by an independent educational grant from Pfizer, Inc.

Certified for CME by:

Provided by:

© Copyright 2013-2017 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.